This low bone formation phenotype appears to be driven by growth-inhibiting signaling from the liver characterized by reductions in igf1 and cyp2r1 in mice with MASLD vs controls. This evidence concerns the gene CYP2R1 and metabolic dysfunction-associated steatotic liver disease.